A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma (NAVIGATOR)

drug protocol number
D5180C00007
drug sponsor
AstraZeneca
drug study
Tezepelumab
drug trial site
KAUH-J
drug status
Completed
drug phase